Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer’s disease in individuals with subjective cognitive decline

Overview of attention for article published in Alzheimer's Research & Therapy, December 2020

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#38 of 1,456)
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

news: 18 news outlets
blogs: 4 blogs

twitter: 14 X users
wikipedia: 1 Wikipedia page

Readers on

mendeley: 71 Mendeley

Summary News Blogs X Wikipedia

So far, Altmetric has seen 4 posts from 4 blogs.

New blood test can determine who’s at risk of Alzheimer’s years before symptoms begin

ZME Science, 07 Jan 2021

Now we just need an efficient treatment.

AnAlzheimer’s disease blood test in the symptom-free stage

Science Blog, 06 Jan 2021

Memory deficit is a normal side effect of aging. At what point does memory loss become pathological? Using a blood test, a…

AnAlzheimer’s disease blood test in the symptom-free stage

ScienceBlog.com, 06 Jan 2021

Memory deficit is a normal side effect of aging. At what point does memory loss become pathological? Using a blood test, a…

A prognostic Alzheimer’s disease blood test in the symptom-free stage

Bioengineer, 06 Jan 2021

Memory deficit is a normal side effect of aging; at what point does memory loss become pathological? Credit: Michael…

This page shows the most recent blog posts that mention this research output.

Click here to find out how to access more activity.